FDA Hears Differing Opinions at Biosimilars Hearing


SILVER SPRING, Md. -- During the second day of the FDA's public meeting on developing an approval pathway for generic versions of biologics, generic manufacturers took a decidedly different view from companies that make brand-name biologics on how the... full

Source: medpagetoday